Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


eISSN: 1643-3750

B7-H4 is Predictive of Poor Prognosis in Patients with Gastric Cancer

YongHui Cui, ZhiHan Li

Department of Gastroenterology, The First People’s Hospital of Shangqiu, Shangqiu, Henan, China (mainland)

Med Sci Monit 2016; 22:4233-4237

DOI: 10.12659/MSM.897781

Available online:

Published: 2016-11-07

BACKGROUND: Recently, some studies were performed to evaluate the relevance of B7-H4 and gastric cancer (GC) prognosis. However, the results remained controversial. Therefore, we performed the present meta-analysis.
MATERIAL AND METHODS: We performed a systematic search in PubMed and Web of Science databases. All data were extracted and reviewed from each eligible study independently by 2 investigators. The strength of association between B7-H4 and GC prognosis was assessed by computing odds ratio (OR) with its corresponding 95% confidence interval (CI).
RESULTS: Six studies that evaluated the association between B7-H4 and GC prognosis were included. The results showed a statistically significant association of B7-H4 and GC prognosis (OR=1.63, 95%CI=1.30–2.03). Furthermore, we conducted subgroup analysis based on source of B7-H4; the results from blood (OR=1.71; 95%CI, 1.09–2.68) and tissue (OR=1.60; 95%CI, 1.03–2.07) indicated B7-H4 was significantly associated with poor prognosis.
CONCLUSIONS: This meta-analysis suggests that GC patients with high B7-H4 have poor prognosis.

Keywords: Neoplasm Staging, Odds Ratio, Prognosis, Stomach Neoplasms - pathology, V-Set Domain-Containing T-Cell Activation Inhibitor 1 - metabolism